Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents pregnancy. Sold as Provera, Depo-Provera, Depo-Subq Provera 104. Every FDA application for this active ingredient: 4 branded and 21 generic.
As of Nov 15, 2026, FDA lists 25 applications for Medroxyprogesterone Acetate (sold as Provera, Depo-Provera, Depo-Subq Provera 104), first approved Jun 18, 1959, with 9 new uses approved and 0 published complete response letters.
First approved: Jun 18, 1959
Applications: 25
New uses approved: 9
Complete response letters: 0
Medicare spending, 2025: $7.6M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Medroxyprogesterone Acetate
Part D
$7.5M
-13%
102,094
Depo-Subq Provera 104
Part D
$66K
+25%
408
Provera
Part D
$29K
-16%
47
Depo-Provera
Part D
$8K
-25%
54
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
MEDROXYPROGESTERONE 10 MG TAB: $0.153 per unitGeneric · +0% in a year
MEDROXYPROGESTERONE 150 MG/ML: $23.04 per MLGeneric · +5% in a year
MEDROXYPROGESTERONE 2.5 MG TAB: $0.115 per unitGeneric · -3% in a year
MEDROXYPROGESTERONE 5 MG TAB: $0.139 per unitGeneric · -6% in a year
DEPO-PROVERA 150 MG/ML SYRINGE: $52.26 per MLBrand · 0% in a year
DEPO-PROVERA 150 MG/ML VIAL: $50.12 per MLBrand · -1% in a year
DEPO-SUBQ PROVERA 104 SYRINGE: $77.45 per MLBrand · 0% in a year
HysronA drug with a new indication and a new dosage for the prevention of premature ovulation during controlled ovarian stimulation. · Kyowa Kirin Co., Ltd. · Mar 11, 2022
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Pfizer
Sandoz
Cipla
Eugia Pharma
Hikma